Showing results (201-210 of 288) with videos related to

Sort By:
Pageof 29
Clinical and Translational Radiation Oncology|February 20, 2020
Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinomaLachlan McDowell, Georgina Casswell, Mathias Bressel, et al.
Oral Oncology|January 23, 2024
Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancerRichard J Young, Christopher Angel, Mathias Bressel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2018
Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists GuidelineCarole Fakhry, Christina Lacchetti, Lisa M Rooper, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2021
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumoursSunit Sarkar, Ben Tran, Lisa Horvath, et al.
The New England Journal of Medicine|June 2, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.
Head & Neck|March 17, 2021
Contralateral neck failure in oral tongue cancer: Outcomes from two centers using predefined treatment criteriaCristian Udovicich, James Daniell, David Wiesenfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2012
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancerQuynh-Thu Le, Richard Fisher, Kelly S Oliner, et al.
Oral Oncology|October 10, 2020
Impact of histological Oral Tongue Cancer margins on locoregional recurrence: A multi-centre retrospective analysisJames Daniell, Cristian Udovicich, David Rowe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b StudyKevin J Harrington, Anthony Kong, Nicolas Mach, et al.
Pageof 29